Microtrast

Barium sulfate, the active ingredient in Microtrast, is a contrast agent presented as an oral radiopaque preparation for gastrointestinal imaging use. It provides high‑density contrast that attenuates X‑rays, allowing clear visualization of the esophagus, stomach, small intestine, colon and rectum during diagnostic procedures.

GNH USA supplies Microtrast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and offers reliable global distribution.

Microtrast, a barium sulfate‑based oral contrast agent, enhances radiographic visualization of the gastrointestinal tract.

- Barium swallow (esophageal imaging): improves delineation of the esophageal lumen and motility patterns. - Barium meal (upper gastrointestinal imaging): outlines the stomach and duodenum for detailed assessment. - Barium enema (lower gastrointestinal imaging): provides contrast of the colon and rectum to detect lesions or structural abnormalities.

Oral barium sulfate may cause a range of adverse reactions, most of which are mild and self‑limiting.

Common Side Effects: - Nausea: mild to moderate feeling of queasiness. - Abdominal cramping: transient discomfort in the stomach or intestines. - Constipation: reduced bowel movements after the procedure. - Diarrhea: loose stools occurring shortly after ingestion. - Metallic taste: temporary alteration of oral sensation. - Vomiting: occasional expulsion of the contrast material.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or anaphylaxis in hypersensitive individuals. - Aspiration pneumonia: inhalation of barium into the lungs leading to infection. - Bowel obstruction: blockage caused by impacted barium in compromised intestines. - Perforation: rare intestinal tear exacerbated by barium pressure. - Severe electrolyte imbalance: significant fluid shifts in vulnerable patients. - Severe dehydration: excessive fluid loss especially with prolonged constipation.

Prior to administering Microtrast, clinicians should observe several precautionary measures to ensure patient safety. - Assess patient history: check for known hypersensitivity to barium sulfate or other contrast agents. - Confirm fasting status: ensure the patient has fasted as recommended to reduce nausea. - Evaluate gastrointestinal integrity: avoid use in suspected perforation, obstruction, or severe inflammation. - Monitor fluid balance: encourage adequate hydration before and after the study to prevent constipation. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Barium sulfate can interact with certain medications or substances that may affect its performance or patient safety.

Major Interactions (Avoid): - Iodinated contrast agents: concurrent use may increase overall radiodensity and complicate image interpretation. - Antacids containing aluminum or magnesium: can alter the consistency of the barium suspension and reduce image quality.

Moderate Interactions (Monitor Closely): - Laxatives: may affect the coating of the gastrointestinal lining and modify contrast distribution. - Diuretics: can influence fluid balance, potentially increasing risk of dehydration. - Opioid analgesics: may slow gastrointestinal motility, altering transit time of the barium preparation.